Cue Biopharma(US:CUE) Globenewswire·2025-11-12 21:05Core Insights - Cue Biopharma, Inc. is making significant progress in advancing its Immuno-STAT platform and lead autoimmune asset, CUE-401, aimed at addressing unmet needs in autoimmune disease treatment [2][4] Business Highlights - The company reported collaboration revenue of $2.1 million for Q3 2025, down from $3.3 million in Q3 2024, attributed to the timing of revenue recognition from collaborations [4] - Research and development expenses decreased to $4.8 million in Q3 2025 from $9.4 million in Q3 2024, mainly due to reduced clinical trial costs and lower employee compensation [5] - General and administrative expenses increased to $4.9 million in Q3 2025 from $2.9 million in Q3 2024, primarily due to a one-time employee severance accrual and higher professional fees [6] Financial Results - The net loss for Q3 2025 was $7.4 million, compared to a net loss of $8.7 million in Q3 2024 [9] - Total operating expenses for Q3 2025 were $9.7 million, down from $12.2 million in Q3 2024 [9] - The company had cash and cash equivalents of $11.7 million as of September 30, 2025, down from $22.5 million at the end of 2024 [11] Strategic Developments - Cue Biopharma announced a strategic collaboration and license agreement with ImmunoScape, which includes upfront payments totaling $15 million and a 40% equity stake in ImmunoScape [7] - The company appointed Usman Azam, M.D., as President and CEO, effective September 29, 2025, to lead the next stage of growth [7] - CUE-401 is designed as a tolerogenic bifunctional molecule aimed at re-establishing immune tolerance and balance [7][12]